Immunotech Laboratories, Inc.
IMMB
Other OTC0.00
USD
- -
- -
ISIN
US45254F2039
CUSIP
45254F203
Return %
Stock
S&P500
1Y
100.00
26.57
3Y
-60.00
76.60
5Y
100.00
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Harry H. Zhabilov Jr. McS
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 120 West Pomona Avenue Monrovia United States of America
- IPO Date
- Dec 1, 2022
- Website
- immunotechlab.com
- Similar Companies
- Business
- Immunotech Laboratories, Inc. is a biotechnology company focused on the research, development, and commercialization of proprietary protein-based therapeutics aimed at treating infectious diseases and immune-related disorders. The company’s core products include its proprietary Irreversible Pepsin Fraction (IPF) protein molecule, marketed under the immune therapeutic vaccine ITV-1. This product is designed for the treatment of HIV/AIDS, hepatitis C, and other debilitating infectious diseases by modulating the immune system. Immunotech is also developing related pediatric treatments, including ITV-2 for pediatric HIV/AIDS. The company operates through a Bulgarian subsidiary, Immunotech Laboratories BG, where it conducts clinical trials, including Phase III testing of its patented immune therapeutic vaccine. Founded in 2000 and headquartered in Monrovia, California, Immunotech transitioned to biotechnology in 2009 after a reverse merger and has been focusing on drug development since then. It holds full indefinite licensing rights to its IPF platform technology and has initiated pre-clinical and clinical testing phases for its treatments. Immunotech Laboratories operates primarily in the biotechnology and pharmaceutical sectors, targeting markets for infectious and immune-related diseases across the US and through clinical activities in Bulgaria. It is a subsidiary of Enzolytics, Inc. since 2017. Recent major developments include the successful completion of Phase III testing of its immune therapeutic vaccine, advancing it closer to commercial viability. The company has also entered a distribution agreement for the territory of Ukraine, marking a step towards the full commercialization of its therapies post-Phase III trials. Immunotech continues to refine and advance its proprietary protein-based therapies with ongoing clinical trials and strategic partnerships aimed at expanding its treatment portfolio and geographic reach. This profile encompasses Immunotech Laboratories' focus on innovative biologic therapeutics, its flagship IPF vaccine platform, strategic clinical development stages, operational footprint spanning the US and Bulgaria, and recent progress in regulatory and commercial milestones in the biotechnology field.